HWAM
ORIC icon

Hennion & Walsh Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

Hennion & Walsh Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-160,054
Closed -$2.03M – 994
2026
Q1 		$2.03M Sell
160,054
-10,018
-6% -$114K 0.07% 350
2025
Q4 		$1.39M Buy
170,072
+23,024
+16% +$265K 0.05% 434
2025
Q3 		$1.76M Sell
147,048
-2,678
-2% -$28.2K 0.06% 378
2025
Q2 		$1.52M Sell
149,726
-6,917
-4% -$46.4K 0.06% 377
2025
Q1 		$874K Sell
156,643
-6,266
-4% -$54.8K 0.04% 500
2024
Q4 		$1.31M Buy
162,909
+24,947
+18% +$229K 0.06% 397
2024
Q3 		$1.41M Buy
137,962
+35,528
+35% +$351K 0.07% 371
2024
Q2 		$724K Buy
+102,434
New +$917K 0.04% 494

Other funds holding ORIC

TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Hennion & Walsh Asset Management's ORIC Position: Q2 2026 in Review

Hennion & Walsh Asset Management sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 160,054 shares — an estimated $2.03M sold.

Hennion & Walsh Asset Management first reported a position in ORIC in Q2 2024 and held it in 8 quarters. The position peaked at $2.03M in Q1 2026. 6 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Hennion & Walsh Asset Management reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 160,054 Oric Pharmaceuticals shares in Q2 2026, an estimated $2.03M.
  • Hennion & Walsh Asset Management first reported a position in Oric Pharmaceuticals in Q2 2024 and held it in 8 quarters.
  • Hennion & Walsh Asset Management's Oric Pharmaceuticals position peaked at $2.03M in Q1 2026.
  • 6 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.